Concepedia

Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines

Anne Julienne Genuino, Usa Chaikledkaew, Anna Melissa Guerrero, Thanyanan Reungwetwattana, Ammarin Thakkinstian

BMC Health Services Research · 2019 · 27 citations · 32 references

DOIFull text

Open access

Abstract

At its current cost, 1 year of adjuvant trastuzumab therapy compared to standard chemotherapy alone for HER2-positive EBC does not represent value for money in the Philippines. Its current cost will have to significantly lower down by one-half to achieve cost-effectiveness.

References

32

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

Antonio C. Wolff, M. Elizabeth Hammond, David G. Hicks et al. · Journal of Clinical Oncology · 2013 · 4K citations · Full text

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Stefan Aebi, T. Davidson, Günther Gruber et al. · Annals of Oncology · 2010 · 2.9K citations · Full text

, , +7

Adjuvant Trastuzumab in HER2-Positive Breast Cancer

Dennis J. Slamon, W. Eiermann, Nicholas J. Robert et al. · New England Journal of Medicine · 2011 · 2.7K citations · Full text

Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology

William J. Gradishar, Benjamin O. Anderson, Ronald Balassanian et al. · Journal of the National Comprehensive Cancer Network · 2018 · 1.6K citations · Full text

, , +15

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Elżbieta Senkus, S. Kyriakides, Shinji Ohno et al. · Annals of Oncology · 2015 · 1.6K citations · Full text

, , +7